- Home
- TARA vs DBI Comparison
TARA vs DBI Comparison
Compare TARA & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- DBI
- Stock Information
- Founded
- TARA N/A
- DBI 1991
- Country
- TARA United States
- DBI United States
- Employees
- TARA N/A
- DBI N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- DBI Clothing/Shoe/Accessory Stores
- Sector
- TARA Health Care
- DBI Consumer Discretionary
- Exchange
- TARA Nasdaq
- DBI Nasdaq
- Market Cap
- TARA 118.1M
- DBI 138.7M
- IPO Year
- TARA N/A
- DBI 1991
- Fundamental
- Price
- TARA $3.03
- DBI $3.26
- Analyst Decision
- TARA Strong Buy
- DBI Hold
- Analyst Count
- TARA 7
- DBI 2
- Target Price
- TARA $20.67
- DBI $3.50
- AVG Volume (30 Days)
- TARA 214.2K
- DBI 1.1M
- Earning Date
- TARA 08-11-2025
- DBI 09-10-2025
- Dividend Yield
- TARA N/A
- DBI 6.15%
- EPS Growth
- TARA N/A
- DBI N/A
- EPS
- TARA N/A
- DBI N/A
- Revenue
- TARA N/A
- DBI $2,949,575,000.00
- Revenue This Year
- TARA N/A
- DBI N/A
- Revenue Next Year
- TARA N/A
- DBI $2.45
- P/E Ratio
- TARA N/A
- DBI N/A
- Revenue Growth
- TARA N/A
- DBI N/A
- 52 Week Low
- TARA $1.60
- DBI $2.18
- 52 Week High
- TARA $10.48
- DBI $8.19
- Technical
- Relative Strength Index (RSI)
- TARA 44.29
- DBI 57.19
- Support Level
- TARA $3.06
- DBI $2.77
- Resistance Level
- TARA $3.33
- DBI $3.55
- Average True Range (ATR)
- TARA 0.17
- DBI 0.25
- MACD
- TARA -0.01
- DBI 0.04
- Stochastic Oscillator
- TARA 4.65
- DBI 71.00
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.